Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Google Halts UK YouTube TV Measurement Service After Legal Action 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
The Maire - EuroChem Case: Three Lessons for Global Business 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
BOULDER, Colo., May 23, 2017 -- UMF Group Inc. (OTC Pink:UMFG) (“the Company”) is pleased to provide a corporate update exemplifying a change in the direction of the business from Oil and Gas Exploration to Medical Marijuana. UMF Group Inc. would like to welcome Nicole Merion, Director of Business Development, to the company. Nicole Merion brings a wealth of scientific knowledge and contacts at the highest levels of academia and production, facilitating UMF Group Inc.’s vision of operating at the cutting edge of technology and research. She also brings a history of production and development to the company and has been working in the Cannabis field for the past ten years.
The company has shifted to an innovative Medical Marijuana company, which aims to develop and approve proprietary extracts as pharmaceuticals, and to ultimately deliver to the market pharmaceuticals that are highly differentiated both from medical marijuana and from current cannabinoid drugs. UMF Group Inc. maintains a proprietary “whole plant” method of extracting various cannabinoids from the marijuana plant and converting them into higher quality and quantity.
Several important events have led to the opportunity of a lifetime for Cannabis Cultivators and Industry Innovators. UMF Group Inc. is poised to make significant strides in the years to come. The US medical cannabis market generated $6.7 billion in sales in 2016, with sales expected to grow to $21.8 billion by 2020. Due to the rapidly changing American situation, with recent favorable legislative changes, in the US, medical cannabis is now legal in 28 states.
The opportunity for market capitalization is not limited to America. Global legal cannabis markets are expected to grow to $140.5 billion in 2020 from $28.8 billion in 2015 according to global market firm Technavio. The Medical Marijuana industry is about to go global and UMF Group Inc. is positioned to be a market leader.
FORWARD LOOKING STATEMENT
This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.
UMF Group Inc. Sean Ross, 360-232-6062 [email protected]
